Statistics

Total Visits

Views
Long-term progression-free-survival (PFS) under sunitinib (SU) treatment for metastatic renal cell carcinoma (Sulong study): Analysis of two populations - long term responders (LR) vs. primary refractory (PR) patients74

Select a period of time:

Number of views in the range

Views
Long-term progression-free-survival (PFS) under sunitinib (SU) treatment for metastatic renal cell carcinoma (Sulong study): Analysis of two populations - long term responders (LR) vs. primary refractory (PR) patients19

Views

Views
November 20253
December 20251
January 20261
February 20261
March 20261
April 20260
May 202612
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States9
Switzerland2
Argentina1
Brazil1
Germany1
Ecuador1
France1
United Kingdom1
Mexico1
Uruguay1
 

Top cities views

Views
Sacramento2
Denver2
Guayaquil1
Los Angeles1
Monte Grande1
Montevideo1
Norfolk1
Portland1
Tupã1
Tuxtla Gutiérrez1